AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7795005 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Case Management (ACM) program
Number of subjects: 0
Study 7795005 — intervention group
Group type: COMPARATOR
Intervention: Hospital program patients
Number of subjects: 0
Study 2920500 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine infusion (0.44 mg/kg)
Number of subjects: 10
Study 2920500 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 1082383 — intervention group
Group type: EXPERIMENTAL
Intervention: TNM1 vaccine
Number of subjects: 21063
Study 1082383 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (Control)
Number of subjects: 21063
Study 31957691 — intervention group
Group type: EXPERIMENTAL
Intervention: Real‐RNI training
Number of subjects: 0
Study 31957691 — intervention group
Group type: COMPARATOR
Intervention: Sham‐RNI training
Number of subjects: 0
Study 30958062 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (300 mg of caffeine)
Number of subjects: 19
Study 30958062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28028822 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tension-free vaginal tapes (TO-TVT)
Number of subjects: 48
Study 25545858 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (dose increased to a maximum of 5 mg/d)
Number of subjects: 503
Study 25545858 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 503
Study 24005782 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care supported by input from remote experts
Number of subjects: 39
Study 24005782 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 39
Study 21806795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage (LL)
Number of subjects: 80
Study 21806795 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's Procedure (HP)
Number of subjects: 80
Study 19099294 — intervention group
Group type: COMPARATOR
Intervention: Cannabis cigarettes containing 0 mg THC (placebo)
Number of subjects: 24
Study 19099294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 29.3 mg THC
Number of subjects: 24
Study 19099294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 49.1 mg THC
Number of subjects: 24
Study 19099294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 69.4 mg THC
Number of subjects: 24
Study 16469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (2 mg twice daily)
Number of subjects: 221
Study 16469601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 15223887 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesic
Number of subjects: 46
Study 15223887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11295378 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the Wisconsin Card Sort Test (WCST‐T)
Number of subjects: 33
Study 11295378 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the Halstead Category Test (CAT‐T)
Number of subjects: 33
Study 11295378 — intervention group
Group type: COMPARATOR
Intervention: No training (No‐T)
Number of subjects: 33
Study 9234921 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cisplatin, vincristine, and bleomycin every 3 weeks for four courses)
Number of subjects: 122
Study 9234921 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 122
Study 9234921 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 122
Study 8215728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (50 to 150 mg/mL for 6 weeks)
Number of subjects: 92
Study 8215728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 3631199 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated accommodative facility training
Number of subjects: 5
Study 29289540 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d (n=67)
Number of subjects: 140
Study 29289540 — intervention group
Group type: COMPARATOR
Intervention: Glargine at a starting dose of 0.1 U/kg/d (n=73)
Number of subjects: 140
Study 29289540 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d
Number of subjects: 140
Study 29289540 — intervention group
Group type: COMPARATOR
Intervention: Glargine at a starting dose of 0.1 U/kg/d
Number of subjects: 140
Study 27474257 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of the proton pump inhibitor (rabeprazole)
Number of subjects: 12
Study 27474257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24743122 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (Antibiotics, systemic metronidazole, antihistamines, traditional external therapy)
Number of subjects: 30
Study 24743122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin Forte (2 capsules per day)
Number of subjects: 30
Study 22023376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake, insulin boluses, and bouts of exercise
Number of subjects: 12
Study 22023376 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor and activity monitor
Number of subjects: 12
Study 22023376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min plasma glucose measurements and plasma insulin and glucagon analyses
Number of subjects: 12
Study 20123226 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA treatment between 0401 and 0800 hours
Number of subjects: 624
Study 20123226 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA treatment between 0000 and 0400 hours
Number of subjects: 624
Study 20123226 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with stroke onset between 1801 and 2400 hours
Number of subjects: 624
Study 20123226 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke onset between 0001 and 0400 hours
Number of subjects: 624
Study 18845005 — intervention group
Group type: EXPERIMENTAL
Intervention: 29G/5-bevel needle with TPE shield
Number of subjects: 5
Study 18845005 — intervention group
Group type: COMPARATOR
Intervention: 27G/3-bevel needle with standard rubber shield
Number of subjects: 5
Study 15833777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.1, 2.1, 2.9, 4.3, 7.1 microg kg(‐1))
Number of subjects: 20
Study 15833777 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.7, 1.4, 4.3, 8.6 microg kg(‐1))
Number of subjects: 20
Study 15833777 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0, 100, 300, 1000, 3000 microg kg(‐1))
Number of subjects: 20
Study 15833777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0, 50, 68, 90 microg kg(‐1))
Number of subjects: 20
Study 15833777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12970212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose target range (INR 1.8 to 2.8 for aortic position and 2.5 to 3.5 for mitral position)
Number of subjects: 3318
Study 12970212 — intervention group
Group type: COMPARATOR
Intervention: Conventional target range (INR 2.5 to 4.5 for all valve positions)
Number of subjects: 3318
Study 12970212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3318
Study 10372723 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg x h)
Number of subjects: 7
Study 10372723 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 9050631 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 20
Study 9050631 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 20
Study 1769820 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 149
Study 1769820 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg daily
Number of subjects: 149
Study 1769820 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 149
Study 6763943 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (Valium)
Number of subjects: 224
Study 6763943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 31831073 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program (13-module training delivered via webinar over 3 months in weekly 60-90 minute sessions)
Number of subjects: 180
Study 31831073 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program
Number of subjects: 180
Study 31831073 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 180
Study 29074542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled RV568 (50 µg)
Number of subjects: 0
Study 29074542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled RV568 (100 µg)
Number of subjects: 0
Study 29074542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled RV568
Number of subjects: 0
Study 29074542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26333723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 189
Study 26333723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang‐2 levels above the median at day 1
Number of subjects: 189
Study 26333723 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification of patients according to Ang‐2 levels at day 3
Number of subjects: 189
Study 26333723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang‐2 concentrations
Number of subjects: 189
Study 23720399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n = 22)
Number of subjects: 42
Study 23720399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-adherence subgroup (from exercise group)
Number of subjects: 42
Study 23720399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-adherence subgroup (from exercise group)
Number of subjects: 42
Study 23720399 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 20)
Number of subjects: 42
Study 22642800 — intervention group
Group type: EXPERIMENTAL
Intervention: Test absorbent pad
Number of subjects: 60
Study 22642800 — intervention group
Group type: COMPARATOR
Intervention: Usual absorbent pad
Number of subjects: 60
Study 18561007 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Administered Interview (SAI)
Number of subjects: 0
Study 18561007 — intervention group
Group type: COMPARATOR
Intervention: Free recall
Number of subjects: 0
Study 17451803 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 100/6 microg bid as maintenance and reliever
Number of subjects: 2760
Study 17451803 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg bid and terbutaline as reliever
Number of subjects: 2760
Study 17451803 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 100/6 microg bid and terbutaline as reliever
Number of subjects: 2760
Study 15832861 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Former therapy
Number of subjects: 45
Study 15832861 — intervention group
Group type: COMPARATOR
Intervention: Conventional myofunctional therapy (Control)
Number of subjects: 45
Study 15896747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1,500 mg twice a day
Number of subjects: 650
Study 15896747 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1.5 to 3 mg/kg in 4 daily doses
Number of subjects: 650
Study 15896747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 650
Study 15896747 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 650
Study 10593427 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate 320 (dimeric, ionic)
Number of subjects: 60
Study 10593427 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 (monomeric, nonionic)
Number of subjects: 60
Study 10593427 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 350 (monomeric, nonionic)
Number of subjects: 60
Study 10593427 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320 (dimeric, nonionic)
Number of subjects: 60
Study 8726758 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP solution
Number of subjects: 97
Study 8726758 — intervention group
Group type: COMPARATOR
Intervention: PEG-ELS
Number of subjects: 97
Study 1819801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber cup polishing with flour of pumice
Number of subjects: 30
Study 1819801 — intervention group
Group type: COMPARATOR
Intervention: Prophy‐Jet airpolishing device
Number of subjects: 30
Study 6758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin and pyrazinamide (regimen 1)
Number of subjects: 833
Study 6758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin (regimen 2)
Number of subjects: 833
Study 6758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 833
Study 6758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (regimen 4)
Number of subjects: 833
Study 6758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly regimen of isoniazid, rifampicin, and ethambutol (regimen 3)
Number of subjects: 833
Study 31094782 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal oxygen administration
Number of subjects: 20
Study 31094782 — intervention group
Group type: COMPARATOR
Intervention: Sham oxygenation
Number of subjects: 20
Study 30299359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 0
Study 30299359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Number of subjects: 0
Study 30299359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam and ceftazidime/avibactam
Number of subjects: 0
Study 27596353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg Q3W
Number of subjects: 520
Study 27596353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q3W
Number of subjects: 520
Study 27596353 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control)
Number of subjects: 520
Study 24735005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% (n=37), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Number of subjects: 81
Study 24735005 — intervention group
Group type: COMPARATOR
Intervention: Hypromellose/dextran 70 as a placebo (n=44), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Number of subjects: 81
Study 22153864 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival Autograft (CAU)
Number of subjects: 87
Study 22153864 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival-Limbal Autograft (CLAU)
Number of subjects: 87
Study 20064211 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-354 (1 mg/kg, 5 mg/kg, or 10 mg/kg)
Number of subjects: 23
Study 20064211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18330081 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin (40 mg/m2) administered intravenously at 4 week intervals
Number of subjects: 22
Study 18330081 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Number of subjects: 22
Study 15677736 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (12‐wk progressive resistance training program of the knee extensor muscles)
Number of subjects: 8
Study 15677736 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 8
Study 15677736 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 8
Study 11923242 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Dk RGP lenses (Dk of 49)
Number of subjects: 42
Study 11923242 — intervention group
Group type: COMPARATOR
Intervention: High-Dk RGP lenses (Dk of 92)
Number of subjects: 42
Study 9862051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day etoposide phosphate (EP)
Number of subjects: 29
Study 9862051 — intervention group
Group type: COMPARATOR
Intervention: 15-day etoposide phosphate (EP)
Number of subjects: 29
Study 7603889 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day)
Number of subjects: 63
Study 7603889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31617768 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator training (EXP)
Number of subjects: 32
Study 31617768 — intervention group
Group type: COMPARATOR
Intervention: On-road training (CMP)
Number of subjects: 32
Study 30194492 — intervention group
Group type: EXPERIMENTAL
Intervention: BRN-01 homeopathic medicine complex (Actheane®)
Number of subjects: 299
Study 30194492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 29716492 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for five days
Number of subjects: 86
Study 29716492 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for three days
Number of subjects: 86
Study 26988768 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg(‐1) body mass plus 0.1 g.kg(‐1) body mass sodium chloride)
Number of subjects: 13
Study 26988768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg(‐1) body mass)
Number of subjects: 13
Study 26988768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg(‐1) body mass) plus caffeine (5 mg.kg(‐1) body mass)
Number of subjects: 13
Study 26988768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 g.kg(‐1) body mass sodium chloride)
Number of subjects: 13
Study 24531987 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with 8 or more friends
Number of subjects: 10578
Study 24531987 — intervention group
Group type: COMPARATOR
Intervention: Adolescents with 0-1 friends
Number of subjects: 10578
Study 24531987 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of adolescents with higher peer status vs. lower peer status
Number of subjects: 10578
Study 24531987 — intervention group
Group type: COMPARATOR
Intervention: Socially disengaged adolescents
Number of subjects: 10578
Study 22528506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol formulations (100 mg) - slow, moderate, and fast releasing
Number of subjects: 0
Study 22528506 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (50 mg)
Number of subjects: 0
Study 22528506 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic solution method
Number of subjects: 0
Study 22528506 — intervention group
Group type: COMPARATOR
Intervention: Oral solution data
Number of subjects: 0
Study 19040679 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (initiated at 500 mg/day for 15 days, then increased to 1000 mg daily, with adjustments permitted within a dosing range of 250-1000 mg daily)
Number of subjects: 241
Study 19040679 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release
Number of subjects: 241
Study 16500701 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for teachers to recognize symptoms of clinical depression
Number of subjects: 151
Study 16500701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training before reporting)
Number of subjects: 151
Study 15312855 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg orally twice daily; NAC group; n = 97
Number of subjects: 192
Study 15312855 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 0.10 microg/kg/min; fenoldopam group; n = 95
Number of subjects: 192
Study 11564104 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark two‐stage (submerged) system (BRS)
Number of subjects: 40
Study 11564104 — intervention group
Group type: COMPARATOR
Intervention: ITI one‐stage (non‐submerged) system (ITI)
Number of subjects: 40
Study 9692411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg twice daily until delivery)
Number of subjects: 283
Study 9692411 — intervention group
Group type: COMPARATOR
Intervention: No treatment (nifedipine given if diastolic pressure exceeded 110 mmHg)
Number of subjects: 283
Study 9692411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 283
Study 9692411 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 283
Study 7820978 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 12
Study 7820978 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12
Study 7820978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 3349009 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2%
Number of subjects: 6
Study 3349009 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 6
Study 3349009 — intervention group
Group type: COMPARATOR
Intervention: Dummy eyedrops
Number of subjects: 6
Study 31642350 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB measured in alternate-order
Number of subjects: 770
Study 31642350 — intervention group
Group type: COMPARATOR
Intervention: TPB measured in ensemble-order
Number of subjects: 770
Study 29496602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple media (TV and Internet) condition
Number of subjects: 160
Study 29496602 — intervention group
Group type: EXPERIMENTAL
Intervention: Single media (TV) condition
Number of subjects: 160
Study 27349416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Pruritus Score (DPS)
Number of subjects: 81
Study 27349416 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 81
Study 27349416 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status questionnaires (EuroQol; EQ-5D)
Number of subjects: 81
Study 27349416 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-related quality of life (Dermatology Life Quality Index; DLQI)
Number of subjects: 81